---
title: "Dose-finding Study Comparing Efficacy and Safety of a PARP Inhibitor Against Doxil in BRCA+ve Advanced Ovarian Cancer"
description: "The purpose of the study is to compare the efficacy and safety of 2 doses of drug AZD2281 against liposomal doxorubicin to see which is effective and well"
url: "https://www.clareohealth.com/clinical-trials/NCT00628251"
---

The purpose of the study is to compare the efficacy and safety of 2 doses of drug AZD2281 against liposomal doxorubicin to see which is effective and well tolerated in treating patients with measurable BRCA1- or BRCA2-positive advanced ovarian cancer and who have failed previous platinum therapy.

## Key Facts

**ID:** NCT00628251
**Status:** COMPLETED
**Phase:** PHASE2
**Type:** INTERVENTIONAL
**Enrollment:** 97
**Sponsor:** AstraZeneca

## Conditions

- Ovarian Neoplasms

## Interventions

**DRUG: AZD2281**
400mg Oral twice daily

**DRUG: Liposomal Doxorubicin**
50mg/m2 Monthly Intravenous

**DRUG: AZD2281**
200mg oral twice daily

## Eligibility

Inclusion Criteria: * Advanced ovarian cancer with positive BRCA1 or BRCA2 status * Progressive or recurrent disease after platinum-based chemotherapy * Measurable disease by RECI…

## Who Can Participate

**Minimum age:** 18

**Maximum age:** 130

**Sex:** FEMALE

**Accepts healthy volunteers:** No

## Study Locations

- Research Site, Los Angeles, California, United States
- Research Site, San Francisco, California, United States
- Research Site, Boca Raton, Florida, United States
- Research Site, Boston, Massachusetts, United States
- Research Site, New York, New York, United States
- Research Site, Houston, Texas, United States
- Research Site, East Melbourne, Australia
- Research Site, Melbourne, Parkville, Australia
- Research Site, Randwick, Australia
- Research Site, Leuven, Belgium
- Research Site, Cologne, Germany
- Research Site, München, Germany
- Research Site, Haifa, Israel
- Research Site, Ramat Gan, Israel
- Research Site, Tel Aviv, Israel
- Research Site, Szczecin, Poland
- Research Site, Barcelona, Spain
- Research Site, Hospitalet deLlobregat, Spain
- Research Site, Lund, Sweden
- Research Site, Cambridge, United Kingdom
- Research Site, Edinburgh, United Kingdom
- Research Site, London, United Kingdom
- Research Site, Manchester, United Kingdom
- Research Site, Sutton, United Kingdom

## Contact Information

## Important Dates

**Study start:** July 30, 2008

**Completion date:** September 19, 2018

**Last updated:** December 5, 2019

[View on ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT00628251)
